The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence

World Journal of Biological Psychiatry

Volumn 12, Issue 3, 2011, Pages 160-187

  Soyka, Michael ^a,b   Kranzler, Henry R ^c   Van Den Brink, Wim ^d   Krystal, John ^e   Möller, Hans Jürgen ^a   Kasper, Siegfried ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Private Hospital Meiringen   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

buprenorphine; clonidine; heroin; lofexidine; maintenance treatment; methadone; naloxone; naltrexone; Opioid dependence

Indexed keywords

BUPRENORPHINE; CLONIDINE; DIAMORPHINE; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; MORPHINE; NALTREXONE;

ANXIETY; ARTICLE; CARDIOTOXICITY; COGNITIVE DEFECT; COMORBIDITY; CONSENSUS DEVELOPMENT; CONSTIPATION; DETOXIFICATION; DISTRESS SYNDROME; DYSPHORIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXEMIA; INSOMNIA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MYALGIA; OPIATE ADDICTION; PRACTICE GUIDELINE; PREGNANCY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TORSADE DES POINTES; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BUPRENORPHINE; CYTOCHROME P-450 CYP2D6; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GENETIC VARIATION; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OXIDOREDUCTASES, N-DEMETHYLATING; PSYCHOTHERAPY; RECEPTORS, OPIOID; SOCIAL SUPPORT; STANDARD OF CARE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 79954435914     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.561872     Document Type: Article

References (330)

1. Abbott PJ 2009. A review of the community reinforecement approach in the treatment of opioid dependence. J Psychoactive Drugs 41:379-385.
2. Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, et al. 2007. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 11:iii-iv, 1-85.
3. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, et al. 2009. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 123:e849-856.
4. Aldrich JV, McLaughlin JP 2009. Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 11:312-322 .
5. Alho H, Sinclair D, Vuori E, Holopainen A. 2007. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75-78. (Pubitemid 46400304)
6. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. 1998. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berlin) 136:217-225. (Pubitemid 28143170)
7. Amass L, Kamien JB, Reiber C, Branstetter S. 2000. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 60(Suppl 1):S6.
8. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. 2008a. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev:CD004147 .
9. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. 2008b. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxifi cation. Cochrane Database Syst Rev:CD005031. DOI: 005010.001002/14651858. CD14005031.pub14651853.
10. American Psychiatric Association Practice Guidelines 2007. Treatment of Patients with Substance Use Disorders, Second edition. Am J Psychiatry 164 4(Suppl).
11. Anglin MD, Almog IJ, Fisher DG, Peters KR. 1989. Alcohol use by heroin addicts: evidence for an inverse relationship. A study of methadone maintenance and drug-free treatment samples. Am J Drug Alcohol Abuse 15:191-207. (Pubitemid 19139801)
12. Arias A, Feinn R, Kranzler HR. 2006. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83:262-268.
13. Auriacombe M, Franques P, Tignol J. 2001. Deaths attributable to methadone vs buprenorphine in France. J Am Med Assoc 285:45. (Pubitemid 32042714)
14. Backmund M, Meyer K, Rothenhaeusler HB, Soyka M. 1998. Opioid detoxifi cation with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol 18:257-258. (Pubitemid 28266897)
15. Backmund M, Schutz CG, Meyer K, Eichenlaub D, Soyka M. 2003. Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients-frequency and correlates of use. Eur Addict Res 9:45-50. (Pubitemid 36160296)
16. Backmund M, Henkel C, Jordan F, Habsch J, Meyer K, K ä ä b S. 2005a. Das QT-Intervall w ä hrend der Substitutionsbehand-lung Heroinabh ä ngiger [in German]. Suchtmed 7:161-164.
17. Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Schutz CG. 2005b. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis 24:17-29. (Pubitemid 43334176)
18. Backmund M, Sch ü tz C, Mayer K, Edlin BR, Reimer J 2009. The risk of emergency treatment due to overdose in injection users. J Addict Dis 89:176-182.
19. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-fi rst revision. World J Biol Psychiatry 9:248-312.
20. Barnett PG, Rodgers JH, Bloch DA. 2001. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96:683-690. (Pubitemid 32458706)
21. Beer B, Rabl W, Libiseller K, Giacomuzzi S, Riemer Y, Pavlic M. 2010. Impact of slow-release oral morphine on drug abusing habits in Austria (in German). Neuropsychiatry 24:108-117.
22. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, et al. 2002. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22:211-215. (Pubitemid 34289398)
23. Berglund M, Thelander S, Jonsson E. 2003. Treating alcohol and drug abuse. An evidence based review. Weinheim: Wiley-VCH.
24. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. 2009. Opiates as antidepressants. Curr pharm Res 15:1612-1622.
25. Bickel WK, Amass L, Crean JP, Badger GJ. 1999. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berlin) 146:111-118. (Pubitemid 29474202)
26. Binder T, Vavrinkova B. 2008. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuroendocrinol Lett 29:80-86.
27. Blanken P, Hendriks VM, van Ree JM, van den Brink W. 2009. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 105:300-308.
28. Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, et al. 2010. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Eur Neuropsychopharmacology 20(Suppl 2):5105-5158.
29. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. 1998. Single-nucleotide polymorphism in the human mu opi-oid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613. (Pubitemid 28506279)
30. Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart F. 2010. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1176-1782.
31. Boulton DW, Arnaud P, DeVane CL. 2001. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70:48-57. (Pubitemid 32678802)
32. Brewer C, Wong VS. 2004. naltrexone: report of lack of hepato-toxicity in acute viral hepatitis, with a review of the literature. Addict Biol 9:81-87. (Pubitemid 38608490)
33. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. 2009. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 35:68-72.
34. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. 2006. Clozapine use and relapse of substance use disorder among patients with co-occuring schizophrenia and substance use disorders. Schizophr Bull 32:637-643. (Pubitemid 44412851)
35. Bunten H, Liang, W-J, Pounder D, Senevirantne C, Osselton MD. 2010. CYP2B6 and OPRMI gene variations predict metha-done-related deaths. Addict Biol 16:142-144.
36. Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, et al. 2009. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 104:1363-1372.
37. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. 1996. Methadone maintenance and addicts ' risk of fatal heroin overdose. Subst Use Misuse 31:177-196. (Pubitemid 26094982)
38. Carroll KM, Chang G, Behr H, Clinton B, Kosten TR. 1995. Improving treatment outcome in pregnant, methadone-main-tained women. Am J Addict 4:56-59.
39. Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, et al. 2001. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: effi cacy of contingency management and signifi cant other involvement. Arch Gen Psychiatry 58:755-761. (Pubitemid 32717799)
40. Castells X, Kosten TR, Capell à D, Vidal X, Colom J, Casas M. 2009. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse 35:339-349.
41. Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond DE Jr. 1981. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 38:1273-1277. (Pubitemid 12228634)
42. Chevillard L, Megarbane B, Faud FJ, Risede P, Decleves X, Mager D, et al. 2010. Mechanisms of respiratory insuffi ciency induced by methadone overdose in rats. Addict Biol 15:62-80.
43. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. 2009. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113-130.
44. Cleary BJ, Donelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, Murphy DJ. 2010. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 105:2071-2084.
45. Cleary M, Hunt G, Matheson S, Siegfried N, Walter G. 2008. Psychosocial intervetions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 23:CD001088.
46. Cook S, Moeschler O, Katarzyna M, Yersin B. 1998. Acute opiate overdose: characteristics of 190 consecutive cases. Addiction 93:1559-1565. (Pubitemid 28472996)
47. Collins ED, Kleber HD, Whittington RA, Heitler NE. 2005. Anesthesia-assisted vs buprenorphine-or clonidine-assisted heroin detoxifi cation and naltrexone induction: a randomized trial. J Am Med Assoc 294:903-913. (Pubitemid 41215459)
48. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. 2006. Injectable, sustained-release naltrex-one for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210-218. (Pubitemid 43213883)
49. Compton P, Ling W, Moody D, Chiang N. 2006. Pharmacokinet-ics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 82:25-31. (Pubitemid 43289101)
50. Condelli WS, Fairbank JA, Dennis ML, Rachal JV. 1991. Cocaine use by clients in methadone programs: signifi cance, scope, and behavioral interventions. J Subst Abuse Treat 8:203-212.
51. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. 2007. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11:iii-iv, 1-171.
52. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. 2004. The effects of methadone and its role in fatalities. Hum Psychop-harmacol 19:565-576. (Pubitemid 40028358)
53. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al. 1997. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14:529-534. (Pubitemid 28053042)
54. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, et al. 2005. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604. (Pubitemid 41773635)
55. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, et al. 2006. ABCB1 and cytochrome P450 genotypes and phenotypes: infl uence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668-681. (Pubitemid 44920225)
56. Crettol S, Besson J, Croquette-Krokar M, H ä mmig R, Gothuey I, Monnat M, et al. 2008. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychaitry 32:1722-1727.
57. Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S. 2001. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychophar-macology (Berlin) 154:153-160. (Pubitemid 32186500)
58. Dahan A. 2006. Opioid-induced respiratory effects: new data on burprenorphine. Br J Anaesth.
59. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. 2006. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96:627-632.
60. Dahan A, Aarts L, Smith T W. 2010. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthe-siology 112:226-238.
61. Darke S, Hall W. 2003. Heroin overdose: Research and evidence-based intervention. J Urban Health 80:189-200. (Pubitemid 37486655)
62. Darke S, Ross J. 2002. Suicide among heroin users: rates, risk factors and methods. Addiction 97:1383-1394. (Pubitemid 35316211)
63. Darke S, Sims J, McDonald S, Wickes W. 2000. Cognitive impairment among methadone maintenance patients. Addiction 95: 687-695. (Pubitemid 30324248)
64. Darke S, Degenhardt L, Mattick R. 2007. Mortality amongst illicit drug users. Epidemiology, causes and intervention. Cambridge: Cambridge University Press.
65. Davids E, Gastpar M. 2004. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 14:209-216. (Pubitemid 38410956)
66. Davis PE, Liddiard H, McMillan TM. 2002. Neuropsychological defi cits and opiate abuse. Drug Alcohol Depend 67:105-108. (Pubitemid 34615933)
67. Day E, Ison J, Strang J. 2005. Inpatient versus other settings for detoxifi cation for opioid dependence. Cochrane Database Syst Rev:CD004580.
68. De Jong CJ. 2005. General anaesthesia is patient-friendly in opioid antagonist detoxifi cation treatment. Addiction 100:1742-1744. (Pubitemid 41626835)
69. De Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JK, van Wilgenburg H, et al. 1998. L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 4:134-141. (Pubitemid 28451413)
70. Deamer RL, Wilson DR, Clark DS, Prichard JG. 2001. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 20:7-14. (Pubitemid 33095745)
71. Degenhardt L, Gibson A, Mattick RP, Hall W. 2008. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and effi cacy. Drug Alcohol Rev 27:1-3.
72. De Leon G, Jainchill N 1991. Residential therapeutic communities for female substance abusers. Bull NY Acad Med 67:277-290.
73. Dobler-Mikola A, Hättenschwiler J, Meili D, Beck T, Böni E, Modestin J. 2005. Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 29:259-265. (Pubitemid 41711937)
74. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. 2005. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496-1509. (Pubitemid 41442319)
75. Drake RE, Xie H, McHugo GJ, Green AI. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441-449. (Pubitemid 30423220)
76. Drake RE, O Neal EL, Wallach MA. 2008. A systematic review of psychosocial research on psychosocial interventions for people with co-occuring severe mental and substance use disorders. J Subst Abuse Treat 34:123-138. (Pubitemid 350216356)
77. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Oto M W. 2008. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165:179-187. (Pubitemid 351704516)
78. Eap CB, Buclin T, Baumann P. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193. (Pubitemid 35398691)
79. EBDD (Europ ä ische Beobachtungsstelle f ü r Drogen und Drogensucht). 2009. Jahresbericht 2009: Stand der Drogen-problematik in Europa [in German]. Luxemburg: Amt f ü r amtliche Ver ö ffentlichungen der Europ ä ischen Union.
80. Ebner N, Rohrmeister K, Winklbaur B, Bauert A, Jagsch R, Peternell A, et al. 2007. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 87:131-138. (Pubitemid 46215932)
81. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. 2006. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 166:1280-1287. (Pubitemid 43967579)
82. Ehret GN, Desmeules JA, Broers B 2007. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Fas 6:289-303. (Pubitemid 46767636)
83. Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, et al. 1997. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81-91. (Pubitemid 27246409)
84. Elsner H. 2005. Kammertachykardien ( " Torsade de Pointes) und weitere Herzrhytmusst ö rungen unter Methadonsubstitiution: Risikominderung durch Medikamentenumstellung [in German]. Suchtmed 7:257-263. (Pubitemid 43041353)
85. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. 2003. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev CD002208.
86. Farre M, Mas A, Torrens M, Moreno V, Cami J. 2002. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 65:283-290. (Pubitemid 34159075)
87. Fareed A, Casarella J, Roberts M, Sleboda M, Amar R, Vayalapalli S, Drexler K. 2009. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis 28:399-405.
88. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. 2010. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis 29:1-14.
89. Farrell M, Neeleman J, Gossop M, Griffi ths P, Buning E, Finch E, et al. 1996. The legislation, organisation and delivery of methadone in 12 EU member states. Brussels: European Commission.
90. Favrat B, Zimmermann G, Zullino D, Krenz S, Dorogy F, Muller J, et al. 2006. Opioid antagonist detoxifi cation under anaesthesia versus traditional clonidine detoxifi cation combined with an additional week of psychosocial support: a randomised clinical trial. Drug Alcohol Depend 81:109-116. (Pubitemid 41821794)
91. Ferri M, Davoli M, Perucci CA. 2010. Heroin maintenance for chronic heroin-dependent individuals: Cochrane Database Syst Rev CD00333410.
92. Fingerhood MI, Thompson MR, Jasinski DR. 2001. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst Abuse 22:193-199. (Pubitemid 37087343)
93. Fischer B, Cruz MF, Patra J, Rehm J. 2008. Predictors of metha-done maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). J Subst Abuse Treat 34: 340-346. (Pubitemid 351318141)
94. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. 2006. Methadone versus buprenor-phine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101:275-281. (Pubitemid 43351601)
95. Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Ammann J, Uchtenhagen A. 2010. Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res 16:131-138.
96. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. 2000. Steady-state pharmacokinetics of (R)-and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50: 427-440.
97. Foster DJ, Somogyi AA, White JM, Bochner F. 2004. Population pharmacokinetics of (R)-, (S)-and rac-methadone in metha-done maintenance patients. Br J Clin Pharmacol 57:742-755. (Pubitemid 38748042)
98. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. 2003. Offi ce-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Engl J Med 349:949-958. (Pubitemid 37064768)
99. Galanter M, Dermatis H, Glickman L, Maslansky R, Sellers MB, Neumann E, et al. 2004. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat 26:313-318. (Pubitemid 38759148)
100. Garbutt JC. 2010. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 16: 2091-2097.
101. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. 2004. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37-45. (Pubitemid 38844575)
102. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, et al. 2003. QT prolongation and Torsades de Pointes in patients infected with human immunodefi ciency virus and treated with methadone. Am J Cardiol 92:995-997. (Pubitemid 37214820)
103. Gish EC, Miller JL, Honey BL, Johnson PN. 2010. Lofexidine, an {alpha}2-receptor agonist for opioid detoxifi cation. Ann Pharmacother 44:343-351.
104. Glatt SJ, Bousman C, Wang RS, Murthy KK, Rana BK, Lasky-Su JA, et al. 2007. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend 90:159-165. (Pubitemid 47299168)
105. Gold MS, Pottash AC, Sweeney DR, Kleber HD. 1980. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopi-ate treatment. J Am Med Assoc 243:343-346. (Pubitemid 10212816)
106. Goldstein A, Herrera J. 1995. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 40:139-150. (Pubitemid 26011977)
107. Gourevitch MN, Friedland GH. 2000. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 67:429-436.
108. Gowing L, Ali R, White J. 2006. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev:CD002025.
109. Gowing L, Farrell M, Ali R, White JM. 2009. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev:CD002024.
110. Gowing L, Ali R, White JM 2010. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev:CD002022.
111. Grabowski J, O'Brien CP, Greenstein R, Ternes J, Long M, Steinberg-Donato S. 1979. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse 6:355-365. (Pubitemid 10163603)
112. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. 2003. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60:81-85. (Pubitemid 36015790)
113. Green AI, Noordsy DL, Brunette MF, O'Keefe C. 2008. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34:61-71. (Pubitemid 350216350)
114. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. 2007. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61:101-110. (Pubitemid 44855745)
115. Greenwald MK, Schuh KJ, Stine SM. 2003. Transferring meth-adone- maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict 12:365-374. (Pubitemid 37175528)
116. Gross A, Marsch LA, Badger GJ, Bickel WK. 2006. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine. Exp Clin Psychopharmacol 14:148-156. (Pubitemid 43988632)
117. Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, et al. 2006. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol 14:157-164. (Pubitemid 43988633)
118. Gruber VA, McCance-Katz EF. 2010. Methadone, buprenor-phine, and street drug interactions with antiretroviral medications. Curr HIV/AIDs Rep 7:152-160.
119. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:85-116.
120. Gutstein HB, Akil H 2001. Opioid analgesics. in: Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 10th ed. Hardman JG, Limbirg LE, Gilman AG, editors. New York: McGraw-Hill. p. 569-620.
121. Haile CN, Kosten TA, Kosten TR. 2008. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34:355-381. (Pubitemid 351913747)
122. Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. 2010. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 28:19-22.
123. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. 2007. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 191:55-62. (Pubitemid 47035182)
124. Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N. 1980. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 37:877-884. (Pubitemid 10034563)
125. Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, et al. 2009. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abuse Treat 36:306-312.
126. Honey BL, Benefi eld RJ, Miller JL, Johnson PN. 2009. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 43:1506-1511.
127. Hser YI, Hoffman V, Grella CE, Anglin MD. 2001. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 58:503-508. (Pubitemid 32411332)
128. Hulse GK, Milne E, English DR, Holman CD. 1997. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92:1571-1579. (Pubitemid 27499568)
129. Hulse GK, Milne E, English DR, Holman CD. 1998. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 93:1033-1042. (Pubitemid 28320995)
130. Hulse GK, English DR, Milne E, Holman CD. 1999. The quantifi cation of mortality resulting from the regular use of illicit opiates. Addiction 94:221-229. (Pubitemid 29068963)
131. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. 2009. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 66:1108-1115.
132. Hulse GK, Ngo HT, Tait RJ. 2010. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry 68:296-302.
133. Iguchi MY, Lamb RJ, Belding MA, Platt JJ, Husband SD, Morral AR. 1996. Contingent reinforcement of group participation versus abstinence in a methadone maintenance program. Exp Clin Psychopharmacol 4:1-7.
134. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. 2005. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26:311-317. (Pubitemid 40733524)
135. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. 1994. Opiate detoxifi cation of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 36:139-145. (Pubitemid 24297674)
136. Janetto PJ, Bratanow NC. 2009. Utilization of pharmacogenom-ics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 10:1157-1167.
137. Jasinski DR, Johnson RE, Kocher TR. 1985. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42:1063-1066.
138. Johnson RE, Jones HE, Fischer G. 2003. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 70:S87-101.
139. Jones HE, Haug NA, Stitzer ML, Svikis DS. 2000. Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addict Behav 25:263-267. (Pubitemid 30114245)
140. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. 2001. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 61:297-306. (Pubitemid 32119311)
141. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. 2005. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79: 1-10. (Pubitemid 41557119)
142. Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. 2008. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 35:245-259.
143. Judson BA, Horns WH, Goldstein A. 1976. Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 20:445-449.
144. Justo D. 2006. Methadone-induced long QT syndrome vs meth-adone-induced torsades de pointes. Arch Intern Med 166:2288; author reply 2289-2290. (Pubitemid 44748783)
145. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 2003. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361:662-668. (Pubitemid 36246548)
146. Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, et al. 2007. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 164:797-803. (Pubitemid 46808535)
147. Kakko J, Heilig M, Sarman I. 2008. Buprenorphine and metha-done treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 96:69-78.
148. Kamien JB, Branstetter SA, Amass L. 2008. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 10:5-18.
149. Kandall SR, Doberczak TM, Jantunen M, Stein J. 1999. The methadone-maintained pregnancy. Clin Perinatol 26:173-183. (Pubitemid 29177807)
150. Kastelic A, Dubajic G, Strbad E. 2008. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 103:1837-1846.
151. Kerr T, Marsh D, Li K, Montaner J, Wood E. 2005. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend 80:329-335. (Pubitemid 41660854)
152. Khantzian EJ, Halliday KS, MacAuliffe WE. 1990. Addiction and the vulnerable self: Modifi ed dynamic group therapy for substance abusers. New York: Guilford.
153. Kharasch ED, Hoffer C, Whittington D, Sheffels P. 2004. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269. (Pubitemid 39221799)
154. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. 2010. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution. Br Med J 341:c3374. doi: 10.1136/bmj.c3172.
155. Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, et al. 1985. Clonidine in outpatient detoxifi cation from methadone maintenance. Arch Gen Psychiatry 42: 391-394. (Pubitemid 15018308)
156. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. 1987. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13:1-17. (Pubitemid 17085752)
157. Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfi eld SF, Kosten TR, et al. 2007. Treatment of patients with substance use disorders, second edition. Am J Psychiatry 164:5-123.
158. Koob GF, Le Moal M 2006. Neurobiology of addiction. Amsterdam: Academic Press.
159. Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD. 1986. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am J Drug Alcohol Abuse 12:1-16. (Pubitemid 16061491)
160. Kosten TR, Rounsaville BJ, Kleber HD. 1987. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch Gen Psychiatry 44:281-284. (Pubitemid 17023143)
161. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. 1990a Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. Am J Psyhiatry 147:1379-1380. (Pubitemid 20346283)
162. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. 1990b Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse 16:329-336.
163. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, et al. 2008. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 122:e601-607.
164. Krantz MJ, Mehler PS. 2006. QTc prolongation: methadone's effi cacy-safety paradox. Lancet 368:556-557. (Pubitemid 44188864)
165. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. 2002. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137:501-504. (Pubitemid 35024621)
166. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. 2003. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23: 802-805. (Pubitemid 36629083)
167. Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B. 2007. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 26:79-85.
168. Krantz MJ, Martin J, Stimmel B, Mehla D, Haigney MC. 2009. QTc interval screening in methadone treatment. Ann Intern Med 150: 387-395.
169. Kreek MJ, Hartman N. 1982. Chronic use of opioids and antip-sychotic drugs. side effects, effects on endogenous opioids, and toxicity. Ann NY Acad Sci 398:151-172. (Pubitemid 13026044)
170. Kreek MJ, Hachey DL, Klein PD. 1979. Stereoselective disposition of methadone in man. Life Sci 24:925-932. (Pubitemid 9157763)
171. Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, et al. 1996. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18: 221-227. (Pubitemid 26159571)
172. Krupitsky EM, Blokhina EA. 2010. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry (in press).
173. Krystal JH, Walker MW, Heninger GR. 1989. Intermittent naloxone attentuates the development of physical dependence on metha-done in rhesus monkeys. Eur J Pharmacol 160:331-338. (Pubitemid 19058176)
174. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. 2001. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Publ Health 91:774-780. (Pubitemid 32397914)
175. Lee TM, Pau CW. 2002. Impulse control differences between abstinent heroin users and matched controls. Brain Inj 16: 885-889. (Pubitemid 35173940)
176. Leri F, Bruneau J, Stewart J. 2003. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 98:7-22. (Pubitemid 36044332)
177. Levin FR, Fischman MW, Connerney I, Foltin RW. 1997. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am J Addict 6:105-116. (Pubitemid 27225447)
178. Ling W, Charuvastra C, Kaim SC, Klett CJ. 1976. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry 33:709-720.
179. Ling W, Wesson DR, Charuvastra C, Klett CJ. 1996. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401-407. (Pubitemid 26149228)
180. Ling W, Amass L, Shoptaw S, Anton JJ, Hillhouse M, Babcock D, et al. 2005. A multi-center randomized trial of buprenor phine, naloxone versus clonidine for opioid detoxifi cation: findings from the National Institute on Drug Abuse Clinical Trial Network. Addiction 100:1090-1100. (Pubitemid 41113602)
181. Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, et al. 2010. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. J Am Med Assoc 304:1578-1583.
182. Lingford-Hughes AR, Welch S, Nutt DJ 2004. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Pharmacology. J Psychopharmacol 18: 293-335. (Pubitemid 39382560)
183. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. 2008. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev:CD006140.
184. Loeber S, Kniest A, Diehl A, Mann K, Croissant B. 2008. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment. Am J Drug Alcohol Abuse 34:584-593.
185. Lotsch J, Geisslinger G. 2005. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82-89. (Pubitemid 40193487)
186. Madlung-Kratzer E, Spitzer B, Brosch R, Dunkel D, Haring C. 2009. A double-blind, randomized, parallel group study to compare the effi cacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxifi cation. Addiction 104: 1549-1557.
187. Mammen K, Bell J. 2009. The clinical effi cacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 10:2537-2544.
188. Manchikanti L, Fellows B, Ailinani H, Pampati V. 2010. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Phys 13:401-435.
189. Mardsen J, Eastwood B, Bradbury C, Dale-Perera A, Farell M, Hammond P, et al. 2009. Effectiveness of community treatments for heroin abd crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 374:1262-1270.
190. Maremmani I, Canoniero S, Pacini M. 2000a. Methadone dose and retention in treatment of heroin addicts with bipolar I disorder comorbidity: preliminary results. Heroin Addict Relat Clin Prob 2:29-46.
191. Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman M, et al. 2000b. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 19:29-41. (Pubitemid 30659340)
192. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. 2005. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 11:44-49. (Pubitemid 40082210)
193. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. 2005. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95:915-918. (Pubitemid 40386816)
194. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. 2003a. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98:441-452. (Pubitemid 36458126)
195. Mattick RP, Kimber J, Breen C, Davoli M. 2003b. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev:CD002207.
196. Mattick RP, Breen C, Kimber J, Davoli M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev:CD 002209.
197. Maxwell JC, Pullum TW, Tannert K. 2005. Deaths of clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend 78:73-81. (Pubitemid 40357684)
198. Maxwell S, Shinderman M, Miner A, Bennet A. 2002. Correlation between Hepatitis C serostatus and methadone dose requirement in 1,163 methadone-maintained patients. Heroin Addict Relat Clin Prob 4:5-10.
199. McCance-Katz EF, Sullivan LE. 2010. Drug interactions of clinical importance among the opioids, methadone and buprenor-phine, and other frequently prescribed medications: A review. Am J Addict 19:4-16.
200. McCowan C, Kidd B, Fahey T. 2009. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. Br Med J 338:b2225.
201. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. 1993. The effects of psychosocial services in substance abuse treatment. J Am Med Assoc 269:1953-1959. (Pubitemid 23106867)
202. Meader N. 2010. A comparison of methadone, buprenorphine and alpha (2) adrenergic agonists for opioid detoxifi cation: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 108:110-114.
203. Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ, 2006. Does high-dose buprenorphine cause respiratory depression?: porrible mechanisms and therapeutic consequences. Toxicol Rev 25:79-85. (Pubitemid 44379890)
204. Megarbane B, Buisien A, Jacobs F, Resiere D, Chevillard L, Vicaut E, Baud FJ. 2010. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 38:403-407.
205. Meili D, Broers B, Bruggmann, Fink A, H ä mmig R. 2008. Medical Recommendations for maintenance therapy in opioid dependence (Swiss Society of Addiction Medicine, in German). Suchtmed 10:29-53. (Pubitemid 351547504)
206. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. 1981. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216:45-54. (Pubitemid 11167856)
207. Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, et al. 2009. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy. Hum Psychop-harmacol 24:524-531.
208. Mintzer MZ. 2007. Effects of opioid pharmacotherapy on psy-chomotor and cognitive performance: A review of human laboratory studies of methadone and buprenorphine. Heroin Addict Relat Clin Prob 9:5-24. (Pubitemid 351359824)
209. Mintzer MZ, Stitzer ML. 2002. Cognitive impairment in metha-done maintenance patients. Drug Alcohol Depend 67:41-51. (Pubitemid 34615927)
210. Mintzer MZ, Copersino ML, Stitzer ML. 2005. Opioid abuse and cognitive performance. Drug Alcohol Depend 78:225-230. (Pubitemid 40544611)
211. Mitchell TB, White JM, Somogyi AA, Bochner F. 2003. Comparative pharmacodynamics and pharmacokinetics of metha-done and slow-release oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 72:85-94. (Pubitemid 37255333)
212. Mitchell TB, White JM, Somogyi AA, Bochner F. 2004. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99:940-945. (Pubitemid 39452805)
213. Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW. 2009. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 28: 226-231.
214. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, et al. 2004. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 75:34-48.
215. Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. 1982. Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]Methadone. J Pharm Sci 71:40-43.
216. National Institute for Health and Clinical Excellence. 2007a. Drug misuse, psychosocial interventions. NICE Clinical Guideline 51, London.
217. National Institute for Health and Clinical Excellence. 2007b. Drug misuse, Opioid detoxifi cation. NICE Clinical Guideline 52, London.
218. National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. 1978. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 35:335-340.
219. Neuman MG, Monteiro M, Rehm J. 2006. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodefi ciency and hepatitis viruses. Subst Use Misuse 41:1395-1463. (Pubitemid 44472465)
220. Ngo HT, Tait RJ, Hulse GK. 2008. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry 65:457-465. (Pubitemid 351519895)
221. Nicholis L, Bragaw L, Ruetsch C. 2010. Opioid dependence tra-etment and guidelines. J Manag Care Pharm 16:S14-21.
222. Nielsen S, Lintzeris N. 2008. The Use of sublingual buprenorphine- naloxone for reversing heroin overdose: a high-risk strategy that should not be recommended. Addiction 103: 2065-2066.
223. Nigam AK, Ray R, Tripathi BM. 1993. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 10:391-394. (Pubitemid 23260531)
224. O'Connor PG, Oliveto AH, Shi JM, Triffl eman EG, Carroll KM, Kosten TR, et al. 1998. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 105:100-105. (Pubitemid 28405231)
225. Okruhlica L, Klempova D. 2000. Hepatitis C infected patients and higher doses of methadone. Heroin Addict Relat Clin Prob 2:57-58.
226. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. 2005. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxifi cation from heroin. Drug Alcohol Depend 77:71-79. (Pubitemid 39656101)
227. Orman JS, Keating GM. 2009. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 69:577-607.
228. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. New Engl J Med 361:777-786.
229. Pau CW, Lee TM, Chan SF. 2002. The impact of heroin on frontal executive functions. Arch Clin Neuropsychol 17:663-670. (Pubitemid 35292279)
230. Peles E, Adelson M. 2006. Gender difefrences and pregnant women in a methadone maintenance trestment (MMT) clinic. J Addict Dis 25:39-45. (Pubitemid 44157067)
231. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. 2007. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 102:289-300. (Pubitemid 46096291)
232. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. 2010. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol (in press).
233. Perron BE, Bunger A, Bender K, Vaughn MG, Howard MO. 2010. Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders? Subst Use Misuse 45:1262-1278.
234. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, et al. 2001. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 62:97-104. (Pubitemid 32149970)
235. Petry NM, Bickel WK, Badger GJ. 1999. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 66:306-314. (Pubitemid 29451763)
236. Petry NM, Bickel WK, Badger GJ. 2000. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction 95: 1069-1077. (Pubitemid 30480266)
237. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, et al. 1986. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67:66-72. (Pubitemid 17193505)
238. Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, et al. 2006. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 83:163-168. (Pubitemid 44218969)
239. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. 2004. A critical review of the causes of death among postmortem toxicological investigations: analysis of 34 buprenor-phine-associated and 35 methadone-associated deaths. Addiction 99:978-988. (Pubitemid 39452810)
240. Prendergast ML, Podus D, Chang E. 2000. Program factors and treatment outcomes in drug dependence treatment: an examination using meta-analysis. Subst Use Misuse 35:1931-1965. (Pubitemid 32004733)
241. Prendergast ML, Urada D, Podus D. 2001. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol 69:389-405. (Pubitemid 32667022)
242. Preston KL, Bigelow GE, Liebson IA. 1990. Effects of sublin-gually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 25:27-34. (Pubitemid 20086950)
243. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. 1999. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 54:127-135. (Pubitemid 29114991)
244. Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II. 2006. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 84:240-247. (Pubitemid 44308379)
245. Reece AS. 2007. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2:35.
246. Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. 2006. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1:109-118.
247. Rosner S, Leucht S, Lehert P, Soyka M. 2008. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22:11-23.
248. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. 2010. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 8: CD004332.
249. SAMHSA (Substance Abuse and Mental Health Services Administration). 2001. National Household Survey on Drug Abuse (NHSDA) [http://www.samhsa.gov].
250. Salamina G, Diedicue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, et al. 2010. Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study. Subst Use Misuse 45:2072-2092.
251. San L, Arranz B, Martinez-Raga J. 2007. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res 13:230-243. (Pubitemid 47414341)
252. Scherbaum N, Finkbeiner T, Leifert K, Gastpar M. 1996. The efficacy of L-methadone and racemic methadone in substitution treatment for opiate addicts-a double-blind comparison. Pharmacopsychiatry 29:212-215. (Pubitemid 26385217)
253. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. 1997. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 54:713-720. (Pubitemid 27344098)
254. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Rob-illard HM, et al. 2000. Methadone maintenance vs 180-day psychosocially enriched detoxifi cation for treatment of opioid dependence: a randomized controlld trial. J Am Med Assoc 283: 1303-1310. (Pubitemid 30129797)
255. Seifert J, Metzner C, Paetzold W, Borutzjy M, Passie T, Rollnik J, et al. 2002. Detoxifi cation of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Phar-macopsychiatry 35:159-164.
256. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. 1999. Clinical guidelines: developing guidelines. Br Med J 318:593-596.
257. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, et al. 1996. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 53:409-415. (Pubitemid 26149229)
258. Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. 1998. Broad benefi cial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 66:811-824. (Pubitemid 28478349)
259. Simmat-Durand L, Lejeune C, Gourarier L. 2009. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 142:119-123.
260. Sinha R, Kimmerling A, Doebrick C, Kosten TR. 2007. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychophar-macology (Berlin) 190:569-574. (Pubitemid 46204473)
261. Somogyi AA, Barratt DT, Coller JK. 2007. Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429-444. (Pubitemid 46364493)
262. Soyka M. 2008a. Safety issues in methadone maintenance, part 1: Legal basis, mortality, and clinical results (in German). Suchtmed 10:7-27. (Pubitemid 351547503)
263. Soyka M. 2008b. Safety issues in methadone maintenance therapy, part 2: Clinical and pharmacological aspects. (in German). Suchtmed 10:119-144. (Pubitemid 352007086)
264. Soyka M, Rösner S. 2010a. Emerging drugs to treat alcoholism. Expert Opinion Emerg Drugs 15:695-711.
265. Soyka M, Rösner S 2010b. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 19:1451-1459.
266. Soyka M, Zingg C. 2009. Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. World J Biol Psychiatry 10:217-224.
267. Soyka M, Horak M, Dittert S, Kagerer S. 2001. Less driving impairment on buprenorphine than methadone in drug-dependent patients? J Neuropsychiatry Clin Neurosci 13: 527-528. (Pubitemid 33140927)
268. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. 2005. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 25:490-493. (Pubitemid 41368375)
269. Soyka M, Apelt SM, Lieb M, Wittchen HU. 2006. One-year mortality rates of patients receiving methadone and buprenor-phine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 26:657-660. (Pubitemid 44772746)
270. Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. 2008a. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World J Biol Psychiatry 9:6-23. (Pubitemid 351250516)
271. Soyka M, Zingg C, Koller G, Kuefner H. 2008b. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 11:641-653. (Pubitemid 351931822)
272. Spanagel R, Kirschke C, Tretter F, Holsboer F. 1998. Forced opiate withdrawal under anaesthesia augments and prolongs the occurrence of withdrawal signs in rats. Drug Alcohol Depend 52:251-256. (Pubitemid 28529583)
273. Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M. 2000. Cognitive-motor performance of metha-done-maintained patients. Eur Addict Res 6:8-19.
274. Spencer L, Gregory M. 1989. Clonidine transdermal patches for use in outpatient opiate withdrawal. J Subst Abuse Treat 6: 113-117. (Pubitemid 19150037)
275. Spiller H, Lorenz DJ, Bailey EJ, Dart RC. 2009. Epidemiological trends in abuse and misuse of presription opioids. J Addict Dis 28:130-136.
276. Simmel B, Cohen M, Sturiano V, Hanbury R, Korts D, Jackson G. 1983. Is treatment for alcoholism effective in persons on methadone maintenance? Am J Psychiatry 140:862-866. (Pubitemid 13060983)
277. Stine SM, Freeman MS, Burns B, Charney DS, Kosten TR. 1992. The effect of methadone dose on cocaine abuse in methadone program. Am J Addict 1:294-303.
278. Stine SM, Grillon CG, Morgan CA 3rd, Kosten TR, Charney DS, Krystal JH. 2001. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychop-harmacology (Berlin) 154:274-281. (Pubitemid 32247188)
279. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH, 2002. Yohimbine-induced withdrawal and anxiety symptoms in opiod-dependent patients. Biol Psychiatry 15:642-651. (Pubitemid 34310501)
280. Stitzer M, Bigelow G. 1978. Contingency management in a meth-adone maintenance program: availability of reinforcers. Int J Addict 13:737-746. (Pubitemid 9076904)
281. Stitzer ML, Bickel WK, Bigelow GE, Liebson IA. 1986. Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients. Drug Alcohol Depend 18:341-348. (Pubitemid 17213878)
282. Stitzer ML, Iguchi MY, Felch LJ. 1992. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 60:927-934.
283. Stoller KB, Bigelow GE, Walsh SL, Strain EC. 2001. Effects of buprenorphine/naloxone in opioid-dependent humans. Psy-chopharmacology (Berlin) 154:230-242. (Pubitemid 32247184)
284. Stotts AL, Dodrill CL, Kosten TR. 2009. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharma-cother 10:1727-1740.
285. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1993a. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 119:23-27. (Pubitemid 23177293)
286. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1993b. Metha-done dose and treatment outcome. Drug Alcohol Depend 33:105-117.
287. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025-1030. (Pubitemid 24208639)
288. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. 1999. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. J Am Med Assoc 281:1000-1005. (Pubitemid 29143891)
289. Strassels SA. 2009. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 15:556-562.
290. Stringer J, Welsh C, Tommasello A. 2009. methadone-associated Q-Z interval prolongation and torsade de pointes. Am J Health Syst Pharm 66:825-833.
291. Strang J, Mardsen J, Cummins M, Farrell M, Finch E, Gossop M, et al. 2000. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibilty and 6-month outcome.Addiction 95:1631-1645.
292. Strang J, Metrablan N, Lintzeris N, Potts L, Carnwath T, Mayet S, et al. 2010. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatm-nent (RIOTT): a randomized trial. Lancet 375:1885-1895.
293. Suffet F, Brotman R. 1984. A comprehensive care program for pregnant addicts: obstetrical, neonatal, and child development outcomes. Int J Addict 19:199-219. (Pubitemid 14116148)
294. Sullivan MA, Vosburg SK, Comer SD. 2006. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berlin) 189:37-46. (Pubitemid 44607258)
295. Tait RJ, Ngo HT, Hulse GK. 2008. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 35:116-124.
296. Termorshuizen F, Krol A, Prins M, van Ameijden EJ. 2005. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 161:271-279. (Pubitemid 40223515)
297. Threlkeld M, Parran TV, Adelman CA. Grey SF, Yu J. 2006. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study. Am J Addict 15:186-191.
298. Tretter F, Burkhardt D, Bussello-Spieth B, Reiss J, Walcher S, Buchele W. 1998. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia. Addiction 93:269-275. (Pubitemid 28067800)
299. Uchtenhagen A. 2010. Heroin-Assisted treatment in Switzerland: a case study in policy change. Addiction 105:29-37.
300. Unger A, Jung E, Winklbaur B, Fischer G. 2010. Gender issues in the pharmacotherapy of opioid-addicted women: buprenor-phine. J Addict Dis 29:217-230.
301. United Nations Office on Drugs and Crime. 2006. 2006 World Drug Report. Vienna: UNODC.
302. Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson Re, Preston KL 2003. Opioid detoxifi cation with buprenorphine, cloni-dine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 69:263-272. (Pubitemid 36293938)
303. Valotassiou V, Wozniak G, Sifakis N, Demakopoulos N, Georgoulias P. 2008. Radiopharmaceuticals in neurological and psychiatric disorders. Curr Clin Pharmacol 3:99-107.
304. Van den Brink W, Haasen C. 2006. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry 51:635-646. (Pubitemid 44526425)
305. Van den Brink W, van Ree JM. 2003. pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13:476-487. (Pubitemid 37433968)
306. Van Dorp EL, Yassen A, Dahan A. 2007. Naloxone treatment in opioid addiction: th3 risks and benefi ts. Expert Opin Drug Saf 6:125-132. (Pubitemid 46380806)
307. Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. 2005. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 78:283-288. (Pubitemid 40694050)
308. Verthein U, Nonorden-Kleij K, Degwitz P, Dilg C, Köhler WK, Passie T, et al. 2008. Long-term effects of heroin-assisted treatment in Germany. Addiction 103:960-966. (Pubitemid 351703473)
309. Walsh SL, June HL, Schuh KJ, Preston Kl, Bigelow GE, Stitzer ML 1995. Effects of buprenorphine and methadone in methadone-maintained subjetcs. Psychopharmacology (Berlin) 119:268-276.
310. Washton AM, Resnick RB, Rawson RA. 1980. Clonidine for outpatient opiate detoxifi cation. Lancet i:1078-1079. (Pubitemid 10097879)
311. Washton AM, Gold MS, Pottash AC. 1984. Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse 4:89-96. (Pubitemid 15180116)
312. Wee S, Koob GF. 2010. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychop-harmacology (Berlin) 210:121-135.
313. Welsh C. 2008. The use of buprenorphine to reverse opoid overdose deserves further evaluation. Addiction 103:2066-2067.
314. Wesson DR, Smith DE. 2010. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs 42:161-175.
315. West SL, O'Neal KK, Graham CW. 2000. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 12:405-414. (Pubitemid 38201228)
316. Wilson RS, Di George WS. 1993. Methadone combined with clo-nidine versus clonidine alone in opiate detoxifi cation. J Subst Abuse Treat 10:529-535. (Pubitemid 24006957)
317. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. 2008a. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 103:1429-1440.
318. Winklbaur B, Jung E, Fischer G. 2008b. Opioid dependence and pregnancy. Curr Opin Psychiatry 21:255-259. (Pubitemid 351489345)
319. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Golz J, et al. 2008. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 95: 245-257.
320. Wobrock T, Soyka M. 2008. Pharmacotherapy of schizophrenia with comorbid substance use disorder-reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 32:1375-1385.
321. Woody GE, Luborsky L, McLellan AT, O'Brien CP, Beck AT, Blaine J, et al. 1983. Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry 40:639-645. (Pubitemid 13094931)
322. Woody GE, McLellan AT, O'Brien CP. 1984. Treatment of behavioral and psychiatric problems associated with opiate dependence. NIDA Res Monogr 46:23-35.
323. Woody GE, McLellan AT, Luborsky L, O'Brien CP. 1987. Twelve-month follow-up of psychotherapy for opiate dependence. Am J Psychiatry 144:590-596. (Pubitemid 17067332)
324. Woody GE, McLellan AT, Luborsky L, O'Brien CP. 1995. Psychotherapy in community methadone programs: a validation study. Am J Psychiatry 152:1302-1308.
325. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. 2008. Extended vs short-term buprenor-phine-naloxone for treatment of opioid-addicted youth: a randomized trial. J Am Med Assoc 300:2003-2011.
326. World Health Organization. 2004. The World Health Report 2004. Geneva: WHO.
327. Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. 2006. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol 38:117-120.
328. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. 2010. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 1187:184-207.
329. Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, et al. 2009. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend 99:28-36.
330. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. 1982. Naltrexone-induced opiate receptor super-sensitivity. Brain Res 245:285-292.